Previous molecular pathophysiological research has identified an abnormal central nervous development, impaired synaptic function, and impaired neural circuit function as the candidate pathogenesis of psychiatric disorders, such as schizophrenia and autism spectrum disorders. However, much remains unknown about the molecular and cellular pathogenesis of these disorders. Induced pluripotent stem cell (iPSC) technology has enabled to study disease-associated neuronal dysfunction using patient-derived neural cells that retain their genetic information. We have established iPSCs from patients that not only possess genetic information but also clinical information such as treatment history data, cognitive function data, personality traits data, neurophysiological data, and brain imaging data. Specifically, we are focusing on monozygotic twin patients with treatment-resistant schizophrenia showing discordant responses to antipsychotic drugs, patients with familial schizophrenia, and patients with disease-associated genomic copy number variations. In addition to these, we are also focusing on de novo mutations occurring in patients that are absent in their parents. Patients'-derived iPSC neurons together with the patients' clinical information are versatile for promoting reverse-translational research, which would contribute to understanding the molecular and cellular pathogenesis of psychiatric disorders and developing therapeutics for these disorders.